Lunit and Labcorp Join Forces to Transform Digital Pathology with AI Innovations

Strategic Collaboration Between Lunit and Labcorp

In a groundbreaking announcement on November 17, 2025, Lunit and Labcorp unveiled their strategic partnership aimed at advancing the field of digital pathology through the application of artificial intelligence (AI) in cancer diagnostics. This collaboration seeks to capitalize on the strengths of both companies—Lunit's pioneering AI technologies and Labcorp's extensive clinical expertise in laboratory services.

Goals of the Collaboration

The primary goal of this partnership is to enhance the analysis and interpretation of tumor microenvironments. By utilizing Labcorp's clinical insights and Lunit's sophisticated AI algorithms, the collaboration aims to unveil new insights that could significantly impact biomarker discovery and improve precision immuno-oncology strategies. The integration of high-resolution whole-slide imaging with AI-powered spatial profiling is expected to revolutionize how pathologists approach cancer diagnosis and treatment decisions.

Initial Findings and Presentations

The first results from this collaborative effort were publicized at two major scientific conferences: the Society for Immunotherapy of Cancer (SITC) and the Association for Molecular Pathology (AMP). At SITC, Lunit demonstrated how AI-driven spatial profiling and machine learning techniques can identify specific immune subtypes associated with non-small cell lung cancer (NSCLC) that carry the MET exon 14 skipping mutation—an important finding, as these subtypes are linked to better outcomes following immunotherapy. The research analyzed over 370 pathology slides, providing a comprehensive characterization of immune phenotypes across different MET alterations.

At the AMP conference, the studies highlighted the varied immune tumor microenvironments associated with distinct MET alterations in NSCLC. For instance, the findings indicated the presence of immune-desert phenotypes in tumors with MET amplifications, in stark contrast to the inflamed phenotypes observed in tumors with MET exon 14 skips.

Impact on Precision Oncology

Daily operations within laboratories and clinical settings could shift dramatically due to this collaboration, as explained by Lunit's CEO, Brandon Suh. He emphasized the importance of collaboration with Labcorp, stating, "Working with Labcorp, one of the most respected leaders in diagnostics and clinical research, is a significant step towards expanding the real-world application of AI in oncology. These preliminary studies clearly showcase how AI can unearth valuable, predictive biomarkers hidden in pathology slides."

Labcorp's vice president and medical lead for oncology, Shakti Ramkissoon, also spoke on the collaboration, noting that the objective is to transform complex pathology data into actionable insights. This partnership aims to illuminate patterns within tumors, ultimately guiding treatment decisions, informing biomarker development, and facilitating more personalized cancer care.

Looking Ahead

The collaboration between Lunit and Labcorp is poised to expand further by applying digital pathology AI in additional cancer types along with genomic correlations, paving the way for advancements in oncology. With Lunit's innovative approaches and Labcorp's clinical expertise, the future of cancer diagnosis and treatment holds promising potential.

About Lunit

Founded in 2013, Lunit (KRX 328130) is dedicated to fighting cancer through AI-powered solutions. The company offers a range of clinically validated technologies that cover medical imaging, breast health, and biomarker analysis. Their aim is to facilitate earlier detection, improve treatment strategies, and achieve precise outcomes across the spectrum of cancer care. Notably, Lunit's platforms have been integrated with other advanced technologies to provide a robust suite that supports cancer diagnosis and treatment in over 10,000 sites across 65 countries.

In conclusion, the partnership between Lunit and Labcorp signifies a key moment in the application of AI in healthcare. As they continue to explore the potential for AI in digital pathology, we can expect to see innovative breakthroughs that will not only enhance our understanding of cancer but also significantly improve patient outcomes in the years to come.